• Most Novel Cancer Drug Approvals Based on Limited Evidence

    13 days ago - By Medscape

    For the majority of novel cancer drugs that gain US approval, the approval is based on a single, often uncontrolled clinical trial that measures surrogate endpoints, with modest clinical benefits to patients.
    Medscape Medical News
    Read more ...